A revolutionary gene therapy trial for young children diagnosed with Hunter syndrome has been given the go ahead in the UK.
The combined phase 1 and 2 clinical trial by University of Manchester researchers, is now open to recruitment and up to five youngsters aged between three and 12 months with the rare lysosomal storage disorder will be treated with autologous hematopoietic stem cell gene therapy.
Professor Brian Bigger, professor of cell and gene therapy at the university, published a paper earlier this month that validates the proof-of-concept outcomes findings in mice.
The researchers hope the findings of their 24-month, single-arm trial into the condition, which is also known as mucopolysaccharidosis type II (MPS II), will remove the need for weekly enzyme replacement therapy over the child’s lifetime.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) approved the clinical trial application and it will be led by Professor Rob Wynn, consultant paediatric haematologist at Royal Manchester Children’s Hospital, Professor Simon Jones, consultant in paediatric inherited metabolic disease at Saint Mary’s Hospital, and Prof Bigger.
Professor Bigger said: “This is a next generation stem cell gene therapy approach, which allows transit of the IDS enzyme into the brain. The newly inserted IDS gene produces an IDS enzyme that contains a proprietary ApoEII-tagged sequence, which can bind to ApoE-dependent receptors on the blood brain barrier, and move enzyme into the brain more efficiently, thus potentially normalizing brain pathology.
“This should speed up delivery of enzyme to the brain, where it is most needed as we can leverage all the enzyme produced by the blood to do this rather than just relying on the engraftment of monocyte cells from the blood into the brain.”
He said the pre-clinical studies they carried out in mice showed the potential to correct disease in the body and normalise brain pathology.
“Mice with Hunter syndrome treated with the HSC gene therapy showed dramatic improvement in their condition, including normalisation of working memory problems, and skeletal features such as the cheekbone dimensions and the width of the humerus and femur bones,” he added.
The trial is the culmination of a more than 15-year effort with Professor Wynn and Professor Jones at MFT to develop HSC gene therapies for neurological lysosomal disorders.
Leave a Reply